• Strategy
  • Payers
  • AI
  • Cybersecurity
  • Device Development
  • Studies/Published Research
  • Ethics
  • Regulatory
  • Digital Biomarkers
  • Data Science
  • Companion Diagnostics
  • Clinical Care
  • Digital Therapeutics
  • Academic Research
  • Virtual Reality
  • RWE
  • Digital Endpoints
  • Medical Devices (Class II and Class III)
  • Commercialization
  • Clinical Trials
  • Drug-Device Combinations
  • SaMD
  • Remote Patient Monitoring
  • Patient Engagement
  • Profiles/Q&A

Brazil Grants Regulatory Approval to ProSense Cryoablation System


The technology, created by IceCure Medical, freezes tumors and is an alternative to surgical intervention.

The Brazilian Health Regulatory Agency (ANVISA) granted regulatory approval to IceCure Medical’s ProSense System. The technology is approved for palliative intervention and the ablation of tumors (both benign and malignant) in skin, liver, lung, breast, prostate, and musculoskeletal tissue.

Eyal Shamir, IceCure’s CEO, said in a press release, “We are very pleased that ProSense has received regulatory approval in Brazil. We expect this to translate into near-term revenues. Early indications of market interest point to strong demand in the largest market in South America where cost-effective, minimally invasive, safe, and effective cryoablation procedures can offer great benefits compared to traditional surgical interventions.”

The technology works by freezing the tumors, which then in turn destroys them. When successful, it works as an alternative to surgical removal.

© 2024 MJH Life Sciences

All rights reserved.